A randomized phase III study in small-cell lung cancer found improved cognitive failure–free survival with brain MRI surveillance alone versus surveillance plus cranial irradiation. The trial also reported preliminary overall-survival results showing no apparent difference between arms. The result suggests an imaging-led strategy can preserve neurocognitive function while avoiding routine cranial irradiation, at least within the trial’s population and follow-up window. The clinical interpretation will depend on longer-term OS, progression patterns, and whether MRI surveillance reliably captures recurrence early enough to guide treatment. For oncology pipeline stakeholders, the trial adds an evidence benchmark for balancing intracranial control against cognitive toxicity in SCLC—an area where treatment intensification and quality-of-life tradeoffs regularly shape practice.